A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
Latest Information Update: 24 Jan 2025
At a glance
- Drugs Giredestrant (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EndomERA
- Sponsors Roche
Most Recent Events
- 23 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2024 Planned End Date changed from 30 Oct 2024 to 31 Dec 2025.
- 11 Jan 2024 Planned primary completion date changed from 30 Oct 2024 to 31 Dec 2025.